Corona Remedies Limited has fixed Friday, June 19, 2026, as the record date to determine member entitlement for the dividend for the financial year 2025-26, pending approval at the 22nd Annual General Meeting (AGM). The AGM is scheduled for Thursday, July 8, 2026, at 11:00 a.m. IST via Video Conferencing (VC) and Other Audio Visual Means (OAVM). The company has dispatched the notice and annual report electronically to members with registered email addresses, while others will receive a letter with the weblink to access the documents.

Key AGM and Voting Details

The remote e-voting facility will be available from Monday, July 6, 2026, at 9:00 a.m. to Wednesday, July 8, 2026, at 5:00 p.m. Members holding shares as on the cut-off date of Thursday, July 2, 2026, are entitled to vote. Those who have not cast votes remotely can vote during the AGM via the e-voting system. The final dividend, if declared, will be paid on or before August 7, 2026.

Agenda and Financial Performance

The AGM agenda includes the adoption of audited standalone and consolidated financial statements for FY 2025-26 and the declaration of a final dividend of ₹10 per equity share. The board has proposed the re-appointment of Mr. Nirav Mehta as Managing Director and CEO and the appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a term of five years from FY 2026-27 to FY 2030-31.

Corona Remedies reported a revenue of ₹1,403.18 crore for FY 2025-26, a surge of 17.28% from ₹1,196.42 crore in the previous year. Adjusted Profit After Tax (PAT) rose by 33.45% to ₹199.42 crore. The company emerged as the fastest-growing entity in the Top 30 of the Indian Pharmaceutical Market (IPM), with its chronic portfolio contributing 71.94% of revenues.

Corona Remedies has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges, detailing its environmental, social, and governance (ESG) performance. The filing, made in accordance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights the company's strategic focus on sustainable manufacturing and ethical business practices. The report discloses a turnover of ₹1,403.18 crore and a net worth of ₹745.97 crore for the fiscal year.

Environmental Initiatives

The company has implemented a Zero Liquid Discharge (ZLD) mechanism at its Bhayla facility, utilizing an Effluent Treatment Plant with a processing capacity of 200 KLD. To reduce its carbon footprint, corona remedies has commissioned a 1.3 MW solar power plant at the Bhayla unit and invested in a 4.25 MW solar park. Additionally, the company has transitioned to LED lighting across its manufacturing facilities to lower electricity consumption.

Social and Governance Metrics

The company reported a total workforce of 5,153 permanent employees and 533 other than permanent employees for F.Y. 2025-26. Women constitute 13% of the Board of Directors and 20% of the Key Managerial Personnel. The report confirms that no human rights grievances or safety-related incidents were recorded during the year. The company maintains a 24/7 Occupational Health Centre and conducts periodic mock drills to ensure workplace safety.

Operational Overview

Corona Remedies operates as a B2C pharmaceutical entity, serving 22 states nationally and 18 countries internationally. Exports accounted for approximately 4.06% of the total turnover. The company focuses on therapeutic areas such as women’s healthcare, cardio-diabetes, and chronic therapies. It ranks fifth in its addressable women’s healthcare market according to Pharmatrac data for December 2025.

Financial and Regulatory Compliance

The company stated that it is compliant with all statutory requirements relevant to the National Guidelines on Responsible Business Conduct (NGRBC) principles. It has not received any adverse orders from regulatory authorities regarding anti-competitive conduct or product safety. The BRSR report has been uploaded to the company's website and forms part of the Annual Report for F.Y. 2025-26.